Cargando…
Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Background. Adalimumab (ADA) is effective for patients with Crohn's disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Methods. Fifteen patients with active biologically na...
Autores principales: | Mizoshita, Tsutomu, Tanida, Satoshi, Tsukamoto, Hironobu, Ozeki, Keiji, Katano, Takahito, Nishiwaki, Hirotaka, Ebi, Masahide, Mori, Yoshinori, Kubota, Eiji, Kataoka, Hiromi, Kamiya, Takeshi, Joh, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009194/ https://www.ncbi.nlm.nih.gov/pubmed/24829572 http://dx.doi.org/10.1155/2014/687257 |
Ejemplares similares
-
Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus
por: Mizoshita, Tsutomu, et al.
Publicado: (2013) -
Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease
por: Ozeki, Keiji, et al.
Publicado: (2012) -
Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016) -
Managing refractory Crohn’s disease: challenges and solutions
por: Tanida, Satoshi, et al.
Publicado: (2015) -
Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)